Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population

被引:107
作者
Zucman, David
de Truchis, Pierre
Majerholc, Catherine
Stegman, Sophia
Caillat-Zucman, Sophie
机构
[1] Hop Necker Enfants Malad, Immunol Lab, APHP, F-75015 Paris, France
[2] Hop Foch, Reseau Ville Hop Val de Sci, Suresnes, France
[3] Hop Raymond Poincare, APHP, Serv Malad Infect, Garches, France
关键词
abacavir hypersensitivity; genetic testing; human leukocyte antigen-B57; screening;
D O I
10.1097/QAI.0b013e318046ea31
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The association of human leukocyte antigen-B*5701 with abacavir hypersensitivity varies depending on ethnic origin. We confirmed the high specificity of B*5701 in the ethnically mixed French population and used a rapid and inexpensive polymerase chain reaction strategy to evaluate the predictiveness of B*5701 screening. The incidence of hypersensitivity decreased from 12% before screening to 0% after screening, and the rate of unwarranted interruptions of abacavir therapy decreased from 10.2% to 0.73%. We therefore recommend the implementation of this cost-effective screen before treatment with abacavir.
引用
收藏
页码:1 / 3
页数:3
相关论文
共 8 条
[1]   Genetic variations in HLA-B region and hypersensitivity reactions to abacavir [J].
Hetherington, S ;
Hughes, AR ;
Mosteller, M ;
Shortino, D ;
Baker, KL ;
Spreen, W ;
Lai, E ;
Davies, K ;
Handley, A ;
Dow, DJ ;
Fling, ME ;
Stocum, M ;
Bowman, C ;
Thurmond, LM ;
Roses, AD .
LANCET, 2002, 359 (9312) :1121-1122
[2]   Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations [J].
Hughes, AR ;
Mosteller, M ;
Bansal, AT ;
Davies, K ;
Haneline, SA ;
Lai, EH ;
Nangle, K ;
Scott, T ;
Spreen, WR ;
Warren, LL ;
Roses, AD .
PHARMACOGENOMICS, 2004, 5 (02) :203-211
[3]   Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J].
Mallal, S ;
Nolan, D ;
Witt, C ;
Masel, G ;
Martin, AM ;
Moore, C ;
Sayer, D ;
Castley, A ;
Mamotte, C ;
Maxwell, D ;
James, I ;
Christiansen, FT .
LANCET, 2002, 359 (9308) :727-732
[4]   HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing [J].
Martin, AM ;
Nolan, D ;
Mallal, S .
TISSUE ANTIGENS, 2005, 65 (06) :571-574
[5]   Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant [J].
Martin, AM ;
Nolan, D ;
Gaudieri, S ;
Almeida, CA ;
Nolan, R ;
James, I ;
Carvalho, F ;
Phillips, E ;
Christiansen, FT ;
Purcell, AW ;
McCluskey, J ;
Mallal, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (12) :4180-4185
[6]   Genetic screening to prevent abacavir hypersensitivity reaction: Are we there yet? [J].
Phillips, EJ .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) :103-105
[7]   Clinical and immunogenetic correlates of abacavir hypersensitivity [J].
Phillips, EJ ;
Wong, GA ;
Kaul, R ;
Shahabi, K ;
Nolan, DA ;
Knowles, SR ;
Martin, AM ;
Mallal, SA ;
Shear, NH .
AIDS, 2005, 19 (09) :979-981
[8]   Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV Cohort study [J].
Rauch, A. ;
Nolan, D. ;
Martin, A. ;
McKinnon, E. ;
Almeida, C. ;
Mallal, Simon .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) :99-102